A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

por Whangbo, Jennifer S., Nikiforow, Sarah, Kim, Haesook T., Wahl, Jonathan, Reynolds, Carol G., Rai, Sharmila C., Kim, Soomin, Burden, Andrew, Alho, Ana C., Lacerda, João F., Alyea, Edwin P., Cutler, Corey S., Ho, Vincent T., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Koreth, John
Publicado 2022

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

por Fathi, Amir T., Kim, Haesook T., Soiffer, Robert J., Levis, Mark J., Li, Shuli, Kim, Annette S., Mims, Alice S., DeFilipp, Zachariah, El-Jawahri, Areej, McAfee, Steven L., Brunner, Andrew M., Narayan, Rupa, Knight, Laura W., Kelley, Devon, Bottoms, AJ S., Perry, Lindsey H., Wahl, Jonathan L., Brock, Jennifer, Breton, Elayne, Ho, Vincent T., Chen, Yi-Bin
Publicado 2022